Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.35 USD
Change Today 0.00 / 0.00%
Volume 428.8K
NAVB On Other Exchanges
Symbol
Exchange
NAVB is not on other exchanges.
As of 8:04 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

navidea biopharmaceuticals i (NAVB) Snapshot

Open
$1.34
Previous Close
$1.35
Day High
$1.36
Day Low
$1.31
52 Week High
12/24/14 - $2.02
52 Week Low
11/12/14 - $0.97
Market Cap
203.0M
Average Volume 10 Days
389.2K
EPS TTM
$-0.23
Shares Outstanding
150.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NAVIDEA BIOPHARMACEUTICALS I (NAVB)

navidea biopharmaceuticals i (NAVB) Related Businessweek News

View More BusinessWeek News

navidea biopharmaceuticals i (NAVB) Details

Navidea Biopharmaceuticals, Inc., a precision medicine company, focuses on the development and commercialization of precision diagnostics, therapeutics, and radiopharmaceutical agents. The company offers Lymphoseek Injection, a receptor-targeted small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients; and Manocept platform to target the CD206 mannose receptor expressed on macrophages. Its development programs include NAV4694, an Fluorine-18 radiolabeled positron emission tomography imaging agent, which is used as an aid in the diagnosis of patients with signs or symptoms of Alzheimer’s disease and mild cognitive impairment; and NAV5001, an Iodine-123 radiolabeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson’s disease and other movement disorders with potential use as a diagnostic aid in dementia. Navidea Biopharmaceuticals, Inc. has research and development agreements with University of California, AstraZeneca AB, and Alseres Pharmaceuticals, Inc. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.

46 Employees
Last Reported Date: 03/16/15
Founded in 1983

navidea biopharmaceuticals i (NAVB) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $82.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $260.0K
Executive Vice President and Chief Business O...
Total Annual Compensation: $314.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $300.0K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $279.1K
Compensation as of Fiscal Year 2014.

navidea biopharmaceuticals i (NAVB) Key Developments

Navidea Biopharmaceuticals, Inc. Enters Agreement with Alseres Pharmaceuticals

Navidea Biopharmaceuticals Inc. announced that it has entered into an agreement with Alseres Pharmaceuticals Inc. to terminate the sub-license agreement dated July 31, 2012 for research, development and commercialization of NAV5001, an agent in Phase 3 clinical development for early detection of Parkinson's disease. Navidea previously announced its intention to decrease its R&D expenses by divesting its non-core neuroimaging assets. This agreement follows through on the Company's commitment to decrease cash burn while moving these neuroimaging programs forward. Under the terms of this agreement, Navidea will transfer the NAV5001 IND, all data, clinical materials, regulatory files (including the Special Protocol Assessment agreements), patents, know-how, and other assets covering the clinical testing of the NAV5001 to Alseres. Alseres will reimburse Navidea on a fully-documented, pass-through basis for any incurred maintenance costs of the contract manufacturer retroactive to March 1, 2015. In addition, as requested by Alseres, Navidea will supply clinical support services for NAV5001 on a cost-plus reimbursement basis. In consideration for the rights granted to Alseres, Navidea will receive a milestone payment in connection with NAV5001's NDA approval by the U.S. FDA and a royalty on subsequent net sales of NAV5001.

Navidea Biopharmaceuticals, Inc. Reports Data at the American Association of Cancer Research Annual Meeting 2015

Navidea Biopharmaceuticals Inc. reported data at the American Association of Cancer Research (AACR) Annual Meeting 2015 demonstrating that the Manocept™ molecule selectively binds to, and is continuously internalized by, tumor-associated macrophages (TAMs) and Kaposi’s sarcoma (KS) tumor cells in a preclinical model. Preliminary results from a clinical study also demonstrated that a single, subcutaneous injection of Technetium Tc 99m tilmanocept (Lymphoseek®), an FDA-approved Manocept-based imaging agent, detects and localizes in KS tumors and the lymph nodes involved in draining the KS tumor fields. Collectively, the data demonstrate the potential for Manocept-based molecules to be used therapeutically to treat Kaposi’s sarcoma. Manocept is designed to target CD206, which is expressed on TAMs and KS tissue. Modulation, including killing or modification of macrophage and KS expression profiles, represents a potential for a paradigm-shifting immunotherapeutic strategy.

Navidea Biopharmaceuticals and Spepharm AG Enter into European Commercial Partnership for Lymphoseek

Navidea Biopharmaceuticals and SpePharm AG entered into an exclusive sublicense agreement for the commercialization and distribution of Lymphoseek 250 microgram kit for radiopharmaceutical preparation (tilmanocept) in the European Union. Under the terms of the agreement, Navidea will receive an upfront payment of $2 million and is eligible to receive additional milestone payments up to $5 million, as well as royalties on European net sales. Under terms of the exclusive license agreement, Navidea will supply Lymphoseek product to Norgine; however, Navidea will transfer responsibility for regulatory maintenance of the Lymphoseek Marketing Authorization to Norgine. Norgine will also be responsible for pricing, reimbursement, sales, marketing, medical affairs, and regulatory. In connection with entering into the agreement, Navidea will be entitled to an upfront payment of $2 million, milestones totaling up to an additional $5 million, as well as royalties on European net sales. The initial territory covered by the agreement includes all 28 member states of the European Economic Community with the option to expand into additional geographical areas.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NAVB:US $1.35 USD 0.00

NAVB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $1.79 USD +0.01
Curis Inc $2.63 USD +0.06
Exact Sciences Corp $22.02 USD +1.12
View Industry Companies
 

Industry Analysis

NAVB

Industry Average

Valuation NAVB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 32.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 26.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NAVIDEA BIOPHARMACEUTICALS I, please visit www.navidea.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.